Skip to main content

Table 2 Epitope binding specificities and enzyme inhibition

From: GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies

Patient (#)

DPA (%)

b96.11 (%)

b78 (%)

N-GAD65Ab (%)

DPC (%)

221-442 (%)

DPD (%)

Remaining Enzyme activity (%)

1*

69

67

65

84

95

100

78

98

2

88

67

65

84

98

98

74

80

3

45

42

48

88

98

98

26

64

4

71

45

72

88

92

103

32

32

5

100

60

100

99

88

102

71

84

6

101

61

76

95

99

100

68

92

7

52

57

60

106

103

99

44

59

8

100

67

65

95

92

100

46

96

9

54

62

86

74

82

96

47

46

10

72

63

52

101

98

95

63

100

11

86

49

65

101

96

100

51

85

12

40

26

53

97

96

102

18

100

13*

52

45

65

88

88

99

34

36

14*

39

55

66

99

82

100

22

26

15*

99

67

90

91

92

89

80

100

16*

97

58

83

100

98

95

79

80

17

76

63

92

NA

NA

NA

76

NA

18

57

17

93

NA

NA

NA

22

NA

19

39

42

49

NA

NA

NA

14

NA

20

37

20

34

NA

NA

NA

12

NA

21

103

94

108

NA

NA

NA

90

63

22

101

100

105

NA

NA

NA

98

81

23

96

102

100

NA

NA

NA

98

54

24

105

102

96

NA

NA

NA

87

13

25

90

84

89

NA

NA

NA

46

4

26

97

64

95

NA

NA

NA

63

22

27

104

85

105

NA

NA

NA

81

62

28

96

96

100

NA

NA

NA

90

67

29

93

71

69

NA

NA

NA

76

68

30

82

74

89

NA

NA

NA

84

73

31

74

58

87

NA

NA

NA

70

43

32

90

96

93

NA

NA

NA

98

30

33*

102

65

78

NA

NA

NA

67

78

34*

100

96

106

NA

NA

NA

92

47

35*

83

91

83

NA

NA

NA

100

53

36*

89

71

82

NA

NA

NA

71

35

37*

95

70

89

NA

NA

NA

88

22

  1. Patients with both T1D and epilepsy are indicated with an asterisk. Samples with highest binding to the DPD-defined epitope and inhibition of enzyme activity are emphasized in bold